SG9706036-2
RTMP
COPY

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/42, 31/38 — A1

(11) International Publication Number: **WO 96/39138**

(43) International Publication Date: 12 December 1996 (12.12.96)

(21) International Application Number: PCT/US96/08875

(22) International Filing Date: 5 June 1996 (05.06.96)

(30) Priority Data:
08/467,475 6 June 1995 (06.06.95) US

(60) Parent Application or Grant
(63) Related by Continuation
US 08/467,475 (CON)
Filed on 6 June 1995 (06.06.95)

(71) Applicant *(for all designated States except US)*: ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: CULLINAN, George, J. [US/US]; Rural Route 1, Box 468, Trafalgar, IN 46181 (US). FONTANA, Steven, A. [US/US]; 14708 Wedgefield Court, Wilmington, NC 28409 (US).

(74) Agents: SALES, James, J. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US).

(81) Designated States: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).

Published
With international search report.
Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: METHODS FOR MINIMIZING BONE LOSS



(I)



(II)

(57) Abstract

The present invention provides a method for minimizing the bone loss effect of a compound of formula (II) or a pharmaceutically acceptable salt thereof, wherein said formula (II) compound is administered to a mammal in need of treatment, comprising concurrently or sequentially administering to said mammal an effective amount of a compound of formula (I), wherein each R^1 is independently -H, -OH, -O(C_1-C_4 alkyl), -OCOC$_6$H$_5$, -OCO(C_1-C_6 alkyl), or -OSO$_2$(C_4-C_6 alkyl); and R^2 is 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino; or a pharmaceutically acceptable salt thereof. Also provided is a method for minimizing bone loss induced by the administration of a formula (II) compound comprising concurrently or sequentially administering a bone anabolic agent. Pharmaceutical compositions are also provided.